---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-001850"
form_type: "8-K"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2024-01-04T23:59:59+00:00"
generated_at: "2026-06-07T04:18:30.217250+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Zymeworks reports $455M cash, runway into 2H 2027; zanidatamab Phase 3 data expected 2024

## Summary
- Preliminary unaudited cash resources of $455M as of Dec 31, 2023; expected funding into second half of 2027.
- Top-line data from Phase 3 HERIZON-GEA-01 trial for zanidatamab in first-line HER2+ GEA expected in 2024.
- Regulatory reviews ongoing in 2024 for zanidatamab in second-line BTC in US and China with Jazz and BeiGene.
- IND filings planned for ZW171 and ZW191 in 2024; ZW220 and ZW251 in 2025; R&D Day in Q4 2024.
- Completed $50M private placement with EcoR1 Capital, contributing to extended cash runway.

## SEC filing metadata
- accession: 0001193125-24-001850
- form_type: 8-K
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2024-01-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000119312524001850/0001193125-24-001850-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000119312524001850/d553940d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-001850
- JSON: https://secwatch.observer/filing/0001193125-24-001850.json
- Plain text: https://secwatch.observer/filing/0001193125-24-001850.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.